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Introduction
Globoid cell leukodystrophy (GLD; Krabbe disease, OMIM 
245200), a hereditary disorder due to mutations in the GALC gene, 
is characterized by deficiency of the hydrolytic lysosomal enzyme 
galactosylceramidase (GALC), which catabolizes the major myelin 
lipid galactosylceramide during normal myelin turnover (1). In the 
infantile form of GLD, undigested galactosylceramide accumula-
tion in macrophages results in globoid cell formation in the central 
nervous system (CNS), and galactolipid inclusions are accumulat-
ed in histiocytes in the peripheral nervous system (PNS). GALC 
is also responsible for the degradation of galactosylsphingosine 
(psychosine), an intermediate in the biosynthesis of cerebrosides. 
Cytotoxic accumulation of psychosine in oligodendrocytes in 
GLD causes cell death. The abnormal turnover of myelin and the 
death of oligodendrocytes compromise normal myelination in the 
developing infant, leading to irritability, paresis/paralysis, hearing 
loss, blindness, decerebration, and death by 2 years of age (2–5). 
Presymptomatic hematopoietic stem cell transplantation (HSCT) 
is the only treatment for infantile GLD; however, long-term out-
comes of transplanted patients remain poor, and morbidity asso-
ciated with the procedure is high (5–9). Moreover, HSCT does not 
treat the PNS disease associated with GLD (5–9). HSCT is no lon-
ger indicated for postsymptomatic patients.
Naturally occurring canine GLD is due to a spontaneous mis-
sense mutation in the GALC gene, c.473A>C (10), and disease pro-
gression in GLD dogs closely recapitulates human disease (10–14). 
The predictable disease progression (onset of neurological dysfunc-
tion at 6 weeks of age) and lifespan (15.7 ± 4.8 weeks of age) (12) allow 
for timely identification of pathological changes and evaluation of 
therapeutic interventions. Intrathecal delivery of adeno-associated 
virus serotype 9 (AAV9) encoding murine GALC to postsymptomat-
ic twitcher mice, a naturally occurring murine model of Krabbe dis-
ease, modestly extended lifespan from 40 to 50.5 days, improved 
pathology, and partially reduced psychosine levels (15). We under-
took a similar strategy in both presymptomatic and postsymptom-
atic GLD dogs, an animal model with a gyrencephalic brain more 
similar in size to an infant’s brain. Herein we demonstrate that a 
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cGALC; Figure 1, A and B). All AAV9-treated dogs received pred-
nisone at an immunosuppressive dose immediately before and for 
4 months after injection. Two cohorts of GLD dogs were treated 
presymptomatically at 2 weeks of age with either a high dose of vec-
tor (2Wk-High, receiving 1 × 1014 vector genomes [vg], n = 10) or a 
lower dose (2Wk-Low, receiving 2 × 1013 vg, n = 4). All 2-week-old 
GLD dogs were neurologically normal at the time of injection. The 
remaining 2 cohorts were treated postsymptomatically at 6 weeks of 
age, again with either a high dose (6Wk-High, receiving 1 × 1014 vg, 
n = 4) or a low dose of vector (6Wk-Low, receiving 2 × 1013, n = 4). All 
6-week-old GLD dogs exhibited tremors and pelvic limb weakness 
at the time of injection. Dogs either were euthanized at 16 weeks of 
age, the mean age of death of untreated GLD dogs, or were followed 
long-term. A control cohort of GLD dogs that received immunosup-
pression regimen alone (IS-only) was also evaluated (Figure 1A).
Untreated GLD dogs developed tremors and pelvic limb weak-
ness at 6 weeks of age and progressed to pelvic limb ataxia, tho-
racic limb dysmetria, and urinary incontinence. Endpoint disease, 
defined as pelvic limb paralysis, occurred at 15.7 ± 4.8 weeks of age 
(12). GLD dogs in the IS-only cohort showed a disease progression 
indistinguishable from that of untreated GLD dogs with endpoint 
disease occurring between 11.0 and 16.4 weeks of age (14.29 ± 2.29 
weeks; P = 0.2954) (Supplemental Video 1, IS-only dog at 10 weeks 
of age; supplemental material available online with this article; 
https://doi.org/10.1172/JCI133953DS1). There was no evidence 
that GLD dogs showed any benefit from IS alone.
single intrathecal injection at the cisterna magna (intracisternal) of 
AAV9 encoding canine GALC (AAV9-cGALC) was capable of clin-
ically, biochemically, and histologically amending both CNS and 
PNS disease, delaying the onset of neurological dysfunction and 
prolonging survival. In fact, presymptomatic delivery of high-dose 
AAV increased lifespan to more than 7 times that of untreated GLD 
dogs, with all treated dogs remaining neurologically normal beyond 
1.5 years of age. Moreover, in this robust evaluation of 26 GLD dogs, 
we demonstrate that this intracisternal protocol is sufficient to glob-
ally deliver therapeutic GALC enzyme, reduce cytotoxic psychosine 
concentrations, and correct the myelination abnormalities present 
in both the CNS and PNS. Importantly, this therapy obviates the 
need for HSCT. Furthermore, our data in the canine GLD model 
confirm a positive effect in dogs treated postsymptomatically, an 
improvement that has not been described in pediatric patients with 
HSCT. Last, the minimal effective dose determined in the canine 
model should inform translation of intrathecal AAV9 gene therapy 
into the clinic for the treatment of Krabbe disease.
Results
Pre- or postsymptomatic intracisternal administration of 1 × 1014 vec-
tor genomes of AAV9-cGALC to GLD dogs mitigates neurological dys-
function. Four cohorts of GLD dogs were injected intrathecally at 
the cisterna magna with AAV9 encoding canine GALC driven by 
a CAGGS promoter, which combines the cytomegalovirus (CMV) 
early enhancer element with the chicken β-actin promoter (AAV9-
Figure 1. Experimental design, vector construct, and survival. (A) GLD dogs were treated with AAV9 delivered to the cisterna magna in a 1-mL volume. 
Ten GLD dogs were treated at 2 weeks of age with 1 × 1014 vg (2Wk-High); 4 GLD dogs were treated at 2 weeks of age with 2 × 1013 vg (2Wk-Low); 4 GLD dogs 
were treated at 6 weeks of age with 1 × 1014 vg (6Wk-High); 4 GLD dogs were treated at 6 weeks of age with 2 × 1013 vg (6Wk-Low). All dogs received an 
immunosuppression protocol consisting of 20 mg/kg intravenous methylprednisolone 1 hour before AAV infusion followed by 4 months of daily oral pred-
nisone (0.5 mg/kg) with a 2-week taper. Four GLD dogs received immunosuppression protocol alone (IS-only). Four 2Wk-High dogs were euthanized at a 
predetermined endpoint of 16 weeks, while the remaining 22 dogs were followed long-term. (B) The AAV9 construct consisted of inverted terminal repeats 
(ITR), a CAGGS promoter, a codon-optimized canine GALC transgene, and a polyadenylation signal. (C) Percentage survival of untreated GLD (black), 
IS-only (gray), 2Wk-High (red), 2Wk-Low (blue), 6Wk-High (green), and 6Wk-Low (purple). A drop in the line indicates a death due to disease progression, 
and a black tick mark indicates dogs still alive (n = 1 in the 6Wk-High cohort, n = 6 in the 2Wk-High cohort). NCV, nerve conduction velocity testing; BAER, 
brainstem auditory evoked response testing.
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at 34.4 and 45.6 weeks of age. One dog in this cohort is currently 
97.1 weeks of age and shows mild pelvic limb ataxia. The remain-
ing dog in this cohort was euthanized at 17 weeks of age owing to 
severe bilateral patellar luxations that limited its ability to walk. 
This confounding orthopedic abnormality is not associated with 
GLD. GLD dogs in the 6Wk-Low cohort fared worse than the 
6Wk-High cohort. All 4 dogs were euthanized between 13.6 and 
32.3 weeks of age (20.89 ± 7.66 weeks, n = 4) owing to pelvic limb 
paralysis; survival time was not significantly different (P = 0.2425) 
from that of GLD dogs that received IS only.
MRI of the brain shows global amelioration of myelination abnor-
malities and atrophy in GLD dogs treated presymptomatically with 
1 × 1014 vg AAV9-cGALC. On T2-weighted images, all 16-week-old 
untreated GLD dogs showed bilaterally symmetrical hyperintensi-
ties, relative to gray matter, of the corona radiata, corpus callosum, 
centrum semiovale, internal capsule (Figure 2B), and cerebel-
lar white matter (not shown) when compared with normal, age-
matched control dogs (Figure 2A). These changes are consistent 
with loss of myelin. Furthermore, brain atrophy, characterized by 
cerebral ventricular dilation and widened sulci, was also seen in 
untreated GLD dogs (Figure 2B). Imaging results of IS-only dogs 
at endpoint were indistinguishable from those of untreated GLD 
dogs showing diffuse white matter hyperintensity (Supplemen-
tal Table 1, MRI) as well as widened sulci (Figure 2C, arrow) and 
enlarged ventricles (Figure 2C, asterisk).
Dogs in the 2Wk-High cohort (Figure 2D) showed white matter 
signal intensities more similar to those of normal dogs (Figure 2A). 
The following white matter structures were normal (hypointense 
Remarkably, all 10 GLD dogs in the 2Wk-High cohort were 
clinically normal at 16 weeks of age. Four dogs in this cohort were 
euthanized for biochemical and histological evaluation of tissues 
at 16 weeks of age, with results presented below. Six of these dogs, 
which are being evaluated long-term, remain neurologically nor-
mal and are currently all over 1.5 years of age (136.0, 128.4, 127.3, 
127.3, 92.0, and 92.0 weeks of age) (Supplemental Video 2, GLD 
2Wk-High at 116 weeks of age; and Figure 1C).
In contrast to the 2Wk-High cohort, each of the 4 dogs in the 
2Wk-Low cohort developed pelvic limb ataxia by 16 weeks of age 
but remained able to walk. In order to evaluate disease progres-
sion in this cohort, no dogs were euthanized at 16 weeks of age and 
all were followed long-term. Three of 4 dogs developed behavioral 
abnormalities (disorientation and anxiety) and postretinal (cen-
tral) blindness by 25 weeks of age. On ophthalmic examination, 
the fundus, retina, and optic disc appeared structurally normal 
(Supplemental Figure 1, C and F). Intriguingly, behavioral chang-
es and blindness were not identified in any dogs in the untreated 
GLD or IS-only cohorts. Endpoint disease, defined as (a) severe 
disorientation with blindness (n = 3) and/or (b) pelvic limb paral-
ysis (n = 2), occurred at 28.6–35.0 weeks of age (P = 0.0002 vs. 
IS only; 30.43 ± 2.65 weeks, n = 4) (Supplemental Video 3, GLD 
2Wk-Low at 27 weeks of age; and Figure 1C).
Assessment of the effect of administration of AAV9-cGALC 
to 6-week-old GLD dogs with signs of neurological dysfunction 
revealed that postsymptomatic therapy was less effective than 
presymptomatic therapy at the respective doses evaluated. Of the 
4 dogs in the 6Wk-High cohort, 2 developed pelvic limb paralysis 
Figure 2. MRI of the brain at 1.5T. T2-weighted images at the level of the caudate nucleus in a normal dog at 16 weeks of age (A), an untreated GLD dog 
at endpoint (16 weeks of age) (B), IS-only at endpoint (16 weeks of age) (C), 2Wk-High at 16 weeks of age (D), 6Wk-Low at endpoint (24 weeks of age) (E), 
6Wk-High at endpoint (34 weeks of age) (F), 2Wk-Low at endpoint (29 weeks of age) (G), and 2Wk-High at 52 weeks of age (H). White arrow in C indicates 
widened sulcus; black asterisk in C indicates enlarged ventricle. White arrow in D indicates hyperintensity of the centrum semiovale relative to gray matter.
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In order to quantify brain atrophy, the areas of the mass 
intermedia and of the cerebellum were determined on mid-sag-
ittal images. The mass intermedia area of the 2Wk-High cohort 
was not different from normal (P = 0.624) and was significant-
ly larger than those of the untreated GLD (P = 0.012), 2Wk-Low 
(P = 0.005), and 6Wk-High (P = 0.011) cohorts. The 2Wk-Low 
(P = 0.011), 6Wk-High (P = 0.020), and 6Wk-Low (P = 0.011) 
cohorts all had mass intermedia areas significantly smaller than 
that of normal dogs. The cerebellar areas of both the 2Wk-High 
and 2Wk-Low cohorts were not different from normal (P = 0.741, 
P = 0.321) and were significantly larger than that of untreated GLD 
dogs (P = 0.010, P = 0.046). Both postsymptomatic cohorts were 
not significantly different from normal or untreated GLD dogs 
(P > 0.05), suggesting an intermediate level of correction. These 
findings demonstrate substantial attenuation of brain atrophy 
with presymptomatic high-dose treatment, but not with low-dose 
or delayed treatment.
Cerebrospinal fluid psychosine, galactosylceramide, and total pro-
tein concentrations are normalized in GLD dogs treated presymptom-
atically with 1 × 1014 vg AAV9-cGALC. Similar to recent findings in 
untreated GLD dogs (16), cerebrospinal fluid (CSF) psychosine 
concentrations were elevated in IS-only dogs at 4 weeks of age and 
increased with disease progression (Figure 3A). Psychosine was 
not detectable in the CSF of normal dogs at any time point. In the 
2Wk-High cohort, psychosine was not detectable in any treated 
animal up to 20 weeks of age; at 24 weeks of age, psychosine was 
detectable in 1 of 6 dogs, and it remained relatively stable beyond 
32 weeks of age. Psychosine was also detectable at a single time 
point, 44 weeks of age, in a second dog of this cohort (Figure 3A). 
Psychosine concentrations were significantly reduced as compared 
with IS-only at 4 (P = 0.020), 8 (P = 0.003), and 12 (P = 0.0004) 
weeks and were not significantly different (P > 0.05) from those in 
relative to gray matter) at 16 weeks of age: corona radiata in 2/4 
dogs; corpus callosum in 4/4 dogs; centrum semiovale in 1/4 dogs; 
internal capsule in 3/4 dogs; and cerebellar white matter in 4/4 
dogs (Supplemental Table 1, MRI). At 52 weeks of age, white mat-
ter signal intensities were normal in the corona radiata (4/6 dogs), 
corpus callosum (5/6 dogs), centrum semiovale (1/6 dogs), internal 
capsule (4/6 dogs), and cerebellar white matter (6/6 dogs) (Figure 
2H). In the 2Wk-Low cohort at endpoint (Figure 2G), signal intensi-
ty was normal in the cerebellum, the brain region nearest the injec-
tion site, in 3/4 dogs; normalization of white matter signal intensity 
did not occur in the corona radiata, centrum semiovale, or inter-
nal capsule in any dog. The dog in this cohort that did not develop 
behavioral abnormalities or blindness was the dog with the least 
white matter signal abnormalities, including normal signal inten-
sity in the corpus callosum and the occipital radiations. In contrast 
to the other cohorts, all dogs (4/4) in the 2Wk-Low cohort at end-
point showed gadolinium enhancement diffusely throughout the 
cerebral white matter including the optic radiations, suggesting an 
inflammatory phase of disease progression (Supplemental Figure 
1, A and D, and Supplemental Table 1, MRI).
In the postsymptomatic cohorts (Figure 2, E and F), white 
matter signal intensity was similar to that in untreated dogs. Nor-
malization of the white matter signal intensity was observed in 
the corpus callosum of 2/7 dogs and in the cerebellar white mat-
ter of 2/7 dogs but was not seen in any other brain region ana-
lyzed (Supplemental Table 1).
For all cohorts, the white matter that showed the most signal 
abnormalities was the centrum semiovale. As this is an initiating 
point for pathology in Krabbe disease, it is plausible that lesions 
were present in the centrum semiovale at the time of treatment. It 
is interesting to note that in the 2Wk-High cohort signal abnormali-
ties in the centrum semiovale remained stable from 16 to 52 weeks.
Figure 3. CSF concentrations of psychosine and galactosylceramide. Psychosine (A) and galactosylceramide (GalCer) (B) were measured by mass spec-
trometry every 4 weeks up to 52 weeks of age. Psychosine and GalCer are reported in ng/mL. Psychosine was below the level of detection in normal dogs. 
Gray shading indicates normal range for canine samples collected at the cisterna magna (<10 ng/mL) for GalCer. IS-only (n = 4, gray circles), 2Wk-High  
(n = 10, ≤16 weeks of age; n = 6, >16 weeks of age; red triangles), 2Wk-Low (n = 4, ≤16 weeks of age; n = 3, >16 weeks of age; blue triangles). Lines represent 
mean with SEM. Nonparametric Kruskal-Wallis test and Mann-Whitney test were performed. A P value of less than 0.05 was considered significant.
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ilarly, the IS-only cohort showed an early and rapid rise in CSF 
GalCer 18:0 (Figure 3B). Normal values are represented by gray 
shading (<10 ng/mL). As seen with psychosine concentration, in 
the 2Wk-High and 2Wk-Low cohorts CSF GalCer 18:0 was signifi-
cantly reduced in comparison with IS-only dogs at 8 (P = 0.0047, 
P = 0.0209) and 12 (P = 0.0047, P = 0.0209) weeks of age, respec-
tively. CSF GalCer in the 2Wk-High cohort was significantly dif-
ferent from normal from 36 to 48 weeks of age (P = 0.0201); how-
ever, it was not significantly different before 36 weeks or at 1 year 
of age (P = 0.1213) (Supplemental Table 1).
Similarly to CSF psychosine and GalCer, CSF total protein 
increased with disease progression in untreated GLD dogs (Sup-
normal age-matched controls at any time point (Supplemental Table 
1). In the 2Wk-Low cohort, the accumulation of psychosine was 
delayed until 12 weeks of age and increased steadily in all dogs until 
endpoint (Figure 3A). The levels remained significantly lower than 
in IS-only dogs at 8 (P = 0.0472) and 12 (P = 0.0202) weeks of age. 
The 2Wk-High cohort was significantly lower than the 2Wk-Low 
cohort from 12 weeks (P = 0.0203) to 28 weeks of age (P = 0.0237). 
These data identify CSF psychosine as a robust, disease-specific 
biomarker of disease severity and therapeutic efficacy.
The natural substrate of GALC, galactosylceramide (GalCer), 
was also significantly elevated in CSF of untreated GLD dogs, and 
18:0 was determined to be the most abundant species (16). Sim-
Figure 4. Motor and sensory nerve conduction velocities at 8, 16, 24, and 52 weeks of age. The motor nerve conduction velocities (NCVs) of the tibial and 
ulnar nerves and the sensory NCVs of the radial nerves were analyzed at 8 weeks of age for normal (n = 7, black squares), 2Wk-High (n = 10, red triangles), 
2Wk-Low (n = 2, blue triangles), 6Wk-High (n = 4, green triangles), 6Wk-Low (n = 4, purple triangles), and IS-only (n = 4, gray circles) (A); 16 weeks of age 
for normal (n = 6), 2Wk-High (n = 9), 2Wk-Low (n = 4), 6Wk-High (n = 4), and 6Wk-Low (n = 2) (B); 24 weeks of age for normal (n = 6), 2Wk-High (n = 6), 
2Wk-Low (n = 3), 6Wk-High (n = 3), and 6Wk-Low (n = 2) (C); and 52 weeks of age for normal (n = 4) and 2Wk-High (n = 6) (D). Lines represent mean with 
SEM. Nonparametric Kruskal-Wallis test and Mann-Whitney test were performed. A P value of less than 0.05 was considered significant.
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plemental Figure 2). In contrast, the 2Wk-High cohort showed 
normal CSF protein (≤30 mg/dL) throughout the entire period of 
observation. The 2Wk-Low and 6Wk-High cohorts showed CSF 
protein concentrations that increased with age and exceeded nor-
mal concentrations by 28 weeks of age, and the 6Wk-Low cohort 
exhibited a more rapid increase in CSF protein that exceeded nor-
mal levels by 16 weeks of age (Supplemental Figure 2). Thus, like 
CSF psychosine and GalCer, total CSF protein is associated with 
disease severity and therapeutic efficacy.
Peripheral nerve conduction velocities and auditory central con-
duction times are improved in GLD dogs treated presymptomatical-
ly with 1 × 1014 vg AAV9-cGALC. Motor (tibial, ulnar) and sensory 
(radial) nerve conduction velocities are significantly reduced in 
untreated GLD dogs as compared 
with normal age-matched control 
dogs, with the degree of velocity 
reduction consistent with demy-
elination (12, 17). IS-only GLD 
dogs were not significantly differ-
ent from untreated GLD dogs in 
the 3 nerves analyzed at 8 weeks 
of age (Figure 4A). At 16 weeks 
of age, the 2Wk-High, 2Wk-Low, 
and 6Wk-High cohorts had nerve 
conduction velocities not signifi-
cantly different from normal for 
each of the 3 nerves analyzed (P > 
0.05) (Figure 4B). At 24 weeks of 
age, the 2Wk-High and 2Wk-Low 
cohorts remained not significant-
ly different from normal, while 
the 6Wk-High cohort showed 
significantly reduced velocities 
for the tibial (P = 0.0201), ulnar 
(P = 0.0201), and radial (P = 
0.0389) nerves (Figure 4C). At 
52 weeks of age, the 2Wk-High 
cohort remained not significantly 
different from normal for the tib-
ial and radial nerves (P > 0.05), 
but showed reduced velocities in 
the ulnar nerve (P = 0.019) (Fig-
ure 4D). The 6Wk-Low cohort 
had significantly slower nerve 
conduction velocity in ulnar (P = 
0.008) and radial (P = 0.0079) nerves at 8 weeks of age. As only 2 
dogs in this cohort lived to 16 weeks of age, statistics could not be 
done. Together, these results reveal that intracisternal delivery of 
AAV9-cGALC was capable of correcting nerve conduction veloci-
ty associated with demyelination when performed presymptomat-
ically, while the postsymptomatic effect was transient.
Brainstem auditory evoked response testing showed that wave 
forms were degraded and central conduction times (I-V peak laten-
cy of waves) were significantly increased in untreated GLD dogs at 
16 weeks of age as compared with normal age-matched controls 
(left ear, P = 0.0105; right ear, P = 0.0196) (Supplemental Figure 
3 and Supplemental Table 1). At 16 weeks of age, the 2Wk-High 
cohort exhibited normalized central conduction times (left ear, 
Figure 5. GALC immunohistochemical 
staining of the brain. IHC staining 
with GALC antibody of the frontal 
lobe, corona radiata/internal capsule, 
and cerebellum in normal dog (A–C), 
IS-only dog (D–F), 2Wk-High dog 
(G–I), and 2Wk-Low dog (J–L). Insets 
show higher-magnification images of 
whole-slide scans. Black arrowheads 
indicate Purkinje cells. gcl, granule cell 
layer; wm, white matter.
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P = 0.4762; right ear, P = 0.3275) that were significantly improved 
in comparison with untreated GLD dogs (left ear, P = 0.0066; 
right ear, P = 0.0132). Similarly, the 2Wk-Low cohort had conduc-
tion times that were not significantly different from normal (left 
ear, P = 0.5169; right ear, P = 0.169) and were significantly reduced 
in comparison with untreated GLD (left ear, P = 0.0339; right ear, 
P = 0.0253). The 6Wk-High cohort had central conduction times 
not significantly different from those in normal or untreated GLD 
(P > 0.05), suggesting an intermediate correction. The 6Wk-Low 
and IS-only cohorts had 2 dogs alive at 16 weeks of age, so sta-
tistics could not be done; however, conduction times remained 
increased (Supplemental Figure 3). 
At 52 weeks of age the 2Wk-High 
cohort remained not significant-
ly different from normal (left ear, 
P = 0.4472; right ear, P = 0.8057). 
Together, these results reveal that 
intracisternal delivery of AAV9-
cGALC was capable of normalizing 
central conduction time when per-
formed presymptomatically.
Global expression of GALC and 
attenuation of both CNS and PNS 
pathology in dogs treated presymptom-
atically with 1 × 1014 vg AAV9-cGALC. 
Immunohistochemical (IHC) stain-
ing with an antibody specific to 
GALC revealed GALC expression at 
low levels in glial cells of the white 
matter throughout the brain of nor-
mal dogs (Figure 5, A–C). GALC 
expression was not detectable in 
cortical neurons (Figure 5A) but was 
present in Purkinje cells (Figure 5C, 
inset, arrowhead). In untreated and 
IS-only dogs (Figure 5, D–F), GALC 
was present throughout the white 
matter in dense regions of globoid 
cell accumulation. GALC expres-
sion was not seen in cortical neurons 
(Figure 5D) and was just at the level 
of detection in Purkinje cells (Figure 
5F, inset, arrowhead). In contrast 
to all other cohorts, in 16-week-
old dogs in the 2Wk-High cohort, 
strong GALC expression in the 
majority of neurons of cortical layer 
V was detected (Figure 5G). GALC 
expression was present in both glia 
throughout the white matter and 
limited globoid cells isolated to the centrum semiovale (Figure 5H 
and Supplemental Table 1, Globoid Cells). In the cerebellum there 
was robust expression of GALC in nearly every Purkinje cell to a 
greater degree than in normal dogs and strong positive expression 
in glial cells in cerebellar white matter (Figure 5I, and inset). Cells 
in the white matter are presumed to be oligodendrocytes based 
on morphology (Figure 5I, inset, wm); however, colabeling with 
GALC and oligodendrocytes was not feasible because of antibody 
incompatibility in canine tissues. In the 2Wk-Low cohort at end-
point, GALC expression was seen throughout the white matter in 
dense regions of globoid cell accumulation (Figure 5, J–L). GALC 
Figure 6. Iron eriochrome staining of 
the brain. Iron eriochrome staining of 
myelin in normal dog (A–C), IS-only dog 
(D–F), 2Wk-High dog (G–I), and 2Wk-Low 
dog (J–L).
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more severe than in the IS-only cohort, likely 
owing to the advanced age of the dogs. Gener-
ally, there was a lessening of globoid cell infil-
tration in the cerebellum, nearest the injection 
site, and spinal cord in the 2Wk-Low cohort 
(Supplemental Table 1).
Both untreated and IS-only–treated GLD 
dogs had marked loss of myelin throughout 
the brain as visualized and semiquantified 
by iron eriochrome stain (Figure 6 and Sup-
plemental Table 1, Demyelination). In the 
2Wk-High cohort, as with globoid cell accu-
mulation, demyelination was isolated to the 
centrum semiovale and corona radiata, which 
corroborates MRI signal intensity findings. 
In the 2Wk-Low cohort at humane endpoint, 
myelination was nearly absent in the most ros-
tral brain as well as the centrum semiovale, cor-
pus callosum, and internal capsule, exceeding 
severity of the IS-only cohort, likely owing to 
the advanced age (Figure 6K and Supplemental Table 1). Myelin 
was more preserved in the cerebellar folia but was diminished in 
the deep cerebellar white matter. These findings corroborate MRI 
findings in which the 2Wk-Low cohort had preservation in the cer-
ebellum but not more rostral brain regions.
We next evaluated regions where gadolinium enhancement 
and presumed blood-brain barrier disruption were detected on 
MRI. Histology showed perivascular cuffing and infiltration of 
lymphocytes (Supplemental Figure 1G) in these regions, in addi-
tion to both severe demyelination (Supplemental Figure 1H) 
and infiltration of periodic acid–Schiff–positive storage granules 
(Supplemental Figure 1I).
In the PNS, GALC enzyme expression was present in numer-
ous Schwann cells (>12 in a ×40 field; Figure 7F) of the tibial nerves 
of dogs in the 2Wk-High cohort. In the 2Wk-Low cohort, substan-
tially fewer GALC-expressing Schwann cells were seen (2 in a ×40 
field; Figure 7E). There also appears to be a subjective increase in 
the expression of myelin basic protein staining in the 2Wk-High 
cohort as compared with the 2Wk-Low cohort (Figure 7, E and 
F). Representative paraphenylenediamine-stained resin sections 
(1 μm) are shown of the tibial nerve. Compared with IS only, there 
was a subjective increase in the population of small- and large-cali-
ber nerve fibers in both AAV-treated cohorts. Active axonal degen-
eration (swollen axons, accumulation of degenerating organelles) 
was absent in the cerebral cortex and present in superficial Purkin-
je cells, but absent in deeper regions of the folia.
The 2Wk-High cohort dog with the lowest level of GALC 
enzyme activity in the internal capsule and cerebellum by enzyme 
assay is represented in Figure 5 to ensure no overrepresenta-
tion. GALC IHC in additional normal, IS-only, 2Wk-High, and 
2Wk-Low dogs can be seen in Supplemental Figure 4. A similar 
pattern of expression was present in all dogs. Supplemental Fig-
ure 4 represents the 2Wk-High dog with the highest level of GALC 
enzyme activity in the cerebellum by enzyme assay so that the 
spectrum of expression can be appreciated. GALC expression 
from a third dog from the 2Wk-High cohort can be seen in the 
graphical abstract.
Globoid cell accumulation is the hallmark pathology in GLD 
and was evaluated in all cohorts by semiquantitation of H&E 
stain (Supplemental Table 1, Globoid Cell Accumulation). The 
IS-only cohort was indistinguishable from untreated GLD dogs, 
with marked, widespread globoid cell accumulation in the white 
matter. In contrast, in the 2Wk-High cohort, throughout the 
entire brain the only presence of globoid cells was in the centrum 
semiovale, the origin of pathology in Krabbe disease, and the 
corona radiata in 1 of 4 dogs (Supplemental Table 1). The globoid 
cell presence was less severe than in the IS-only and 2Wk-Low 
cohorts. In the 2Wk-Low cohort, globoid cell accumulation was 
Figure 7. Light-level 1-μm resin sections and GALC 
immunofluorescence of tibial nerve. Resin- 
embedded samples from the tibial nerve were 
stained with paraphenylenediamine, then evaluated 
in 1-μm sections. (A) Normal dog 16 weeks of age. (B) 
IS-only 13 weeks of age. (C) 2Wk-Low 29 weeks of 
age. (D) 2Wk-High 16 weeks of age. (E and F) Immu-
nofluorescent staining for GALC in red and myelin 
basic protein in green at ×40 original magnification 
in 2Wk-Low (E) and 2Wk-High (F) cohorts. Arrows in 
B and C point to myelin ovoids. Insets show Schwann 
cells at high magnification (×100). Scale bars: 25 μm, 
A–D; 50 μm, E and F.
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cisternal injection of high-dose AAV9-cGALC, GALC expression 
is evident in Schwann cells and myelination is clearly improved.
Finally, given recent concern regarding toxicity to the dorsal 
root ganglia associated with AAV administration, we examined 
dorsal root ganglia as well as spinal cord gray matter. Within these 
regions we identified neuronal cytoplasmic swelling and Nissl sub-
stance loss (Supplemental Figure 5, red arrow) and, less frequently, 
cytoplasmic vacuolation (Supplemental Figure 5B, black arrow) with 
occasional accumulation of brightly eosinophilic granules (Supple-
mental Figure 5, blue arrows) and adjacent axonal swelling. These 
changes are unusual and may represent a secondary lesion due to 
chronic neuronal degeneration or axonal damage. This change is 
seen in most animals and is therefore likely unrelated to the treat-
ment. A few animals also had minimal multifocal increased cellu-
larity in the dorsal root ganglia, which may represent inflammatory 
cell infiltrates (Supplemental Figure 5C, green arrow); however, this 
was present across cohorts and thus is likely unrelated to treatment.
was not observed in any cohort; however, rare myelin ovoids 
consistent with end-stage axonal degeneration were found in the 
IS-only (Figure 7B, arrow) and 2WK-Low GLD (Figure 7C, arrows) 
cohorts. Myelin ovoids were not found in the 2WK-High GLD (Fig-
ure 7D) cohort. Myelinated fiber density (MFD; myelinated fibers/
mm2) of the tibial nerve of normal 16-week-old dogs was deter-
mined to be 9891.5 ± 1704.7 and the percentage of thinly myelin-
ated fibers (<5 μm) 23.8% ± 3.1% (n = 4) (Figure 7A). Untreated 
GLD dogs had a reduction in MFD to 7764 ± 1734 and an increase 
in the percentage of thinly myelinated fibers to 31.4% ± 7.1% (n = 
4). In the 2Wk-Low dose cohort, data were available from 2 dogs 
with MFD of 9940 and 5544 and percentage of thinly myelinated 
fibers 23.7% and 15.2%, respectively (Figure 7C). The 2Wk-High 
dose cohort showed improvement over untreated GLD dogs with 
MFD in 2 dogs with data available at 7632 and 11,025 and per-
centage of thinly myelinated fibers 27.1% and 26.1%, respectively 
(Figure 7D). Together, our results indicate that after a single intra-
Figure 8. Psychosine concentration and GALC enzyme activity. Psychosine concentration was determined by mass spectrometry and GALC enzyme 
activity was measured using a synthetic 4MU substrate in punch biopsies taken from flash-frozen tissue samples of the frontal cortex, internal capsule, 
cerebellar white matter, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, sciatic nerve, liver, kidney, spleen, lung, heart, biceps, and quadriceps. 
Psychosine (A and C) is reported in pmol/mg protein and GALC enzyme activity (B and D) in pmol/μg protein per hour. IS-only cohort at endpoint (n = 4, 
gray circles), 2Wk-High cohort at 16 weeks of age (n = 4, red triangles), 2Wk-Low cohort at endpoint (n = 4, blue triangles), normal at 16 weeks of age (n = 
4, black squares). Lines represent mean with SEM. Nonparametric Kruskal-Wallis test and Mann-Whitney test were performed. A P value of less than 0.05 
was considered significant.
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with the psychosine and GALC data, vg copies were significant-
ly increased in the 2Wk-High cohort as compared with untreated 
dogs in all CNS tissues (frontal cortex, P = 0.02; cerebellar white 
matter, P = 0.02; cervical spinal cord, P = 0.02; thoracic spinal 
cord, P = 0.02; and lumbar spinal cord, P = 0.02) except the inter-
nal capsule. The 2Wk-Low cohort had significantly increased vg 
copies as compared with untreated animals in the frontal cortex 
(P = 0.03) and thoracic (P = 0.03) and lumbar (P = 0.03) spinal 
cord. However, all CNS tissues had significantly fewer vg copies 
than the 2Wk-High cohort (P < 0.05) except the internal capsule 
(Supplemental Table 1, Vector Genome Copies). The sciatic nerve 
was not analyzed for vg copies because of the limited amount of 
tissue for biochemistry (GALC and psychosine) and histology. In 
somatic tissues, the 2Wk-High cohort had a significant increase in 
vg copies as compared with untreated animals in all tissues except 
the quadriceps. The 2Wk-Low cohort had significantly more vg 
copies than untreated animals only in the liver (P = 0.03) and kid-
ney (P = 0.03), and had significantly fewer vgs than the 2Wk-High 
cohort in all tissues except the quadriceps (Supplemental Table 1, 
Vector Genome Copies). Our results indicate that an intracisternal 
injection of AAV9 is capable of disseminating therapeutic trans-
genes throughout the CNS and somatic tissues, with the greatest 
number of vg copies in the spinal cord and liver, and with copies 
persisting for at least 16 weeks. These studies in a large-animal 
model provide strong evidence that a single injection of AAV9 into 
the CSF is capable of distributing functional therapeutic enzyme 
to the CNS, PNS, and somatic tissues where long-term expression 
prevents substrate accumulation, preserves myelin integrity, and 
prevents disease progression in a clearly dose-dependent manner.
Discussion
In GLD, both CNS and PNS myelination abnormalities occur, 
resulting in cognitive decline and motor deterioration that ulti-
mately results in early death. Newborn screening for Krabbe 
disease is currently performed in many states, allowing for treat-
ment of presymptomatic babies with HSCT. The exact thera-
peutic mechanism of HSCT is unknown; however, it is believed 
to involve transit of GALC-positive donor-derived monocytes 
into the CNS, which allows secretion of GALC to be endocyto-
sed by neurons and glia via the mannose-6-phosphate receptor 
to cross-correct the enzyme deficiency (18). There are also data 
showing that HSCT has a significant immunomodulatory effect 
(19). Although HSCT is the standard of care for presymptomat-
ic Krabbe infants, the majority of treated patients show limited 
improvements in motor ability and PNS myelination (5–9). Treat-
ed children are frequently wheelchair bound, unable to commu-
nicate effectively, and respirator dependent for an extended time. 
As HSCT in postsymptomatic children provides no increase in 
survival (6), it is no longer indicated for babies diagnosed beyond 
a couple of months of age. Clearly, there is a need for more effec-
tive therapies that treat both CNS and PNS aspects of disease at 
both presymptomatic and postsymptomatic stages.
Intrathecal administration of AAV9 permits dissemination 
of transgenes throughout the nervous system and is current-
ly in clinical trials for the treatment of neuronal ceroid lipo-
fuscinosis 3 (CLN3; ClinicalTrials.gov NCT03770572), CLN6 
(NCT02725580), spinal muscular atrophy (NCT03381729), and 
Psychosine, GALC enzyme activity, and vector copy quantifica-
tion in AAV9-GALC–treated dogs. Remarkably, in the 2Wk-High 
cohort at 16 weeks of age, psychosine concentration was signifi-
cantly reduced in comparison with IS-only dogs in all CNS tissues 
analyzed (frontal cortex, P = 0.02; internal capsule, P = 0.02; cer-
ebellar white matter, P = 0.02; cervical spinal cord, P = 0.02; tho-
racic spinal cord, P = 0.02; lumbar spinal cord, P = 0.02) as well 
as in the sciatic nerve (P = 0.02) (Figure 8A). The internal capsule 
remained significantly higher than normal (P = 0.02); however, 
no other CNS or PNS tissues had psychosine values significant-
ly different from those in normal age-matched control dogs (P 
> 0.05). Interestingly, in the cerebellar white matter and sciatic 
nerve, where GALC enzyme activity exceeded normal (Figure 
8B), psychosine levels were 1.9- and 1.3-fold lower than normal, 
respectively. In the 2Wk-Low cohort, significant reduction of psy-
chosine was seen only in the lumbar spinal cord (P = 0.02) (Figure 
8A). Further, all nervous system tissue had psychosine values that 
remained significantly higher than in normal age-matched control 
dogs and the 2Wk-High cohort (P < 0.05).
In somatic tissues, the 2Wk-High cohort’s lung psychosine lev-
els were significantly reduced as compared with those of IS-only 
dogs (P = 0.02) and not significantly different from those of nor-
mal age-matched control dogs (P > 0.05) (Figure 8C). In the kid-
ney, the psychosine concentration was not significantly different 
from that in the IS-only or the normal cohort. Numerous tissues 
from the 2Wk-High cohort had psychosine concentrations below 
the level of detection (liver, spleen, heart, biceps, and quadri-
ceps). In contrast, the 2Wk-Low cohort had detectable levels of 
psychosine that were not significantly reduced as compared with 
IS-only–treated dogs in every somatic tissue sampled (Figure 8C). 
Additionally, liver, lung, and biceps psychosine levels remained 
significantly higher than in normal age-matched control and 
2Wk-High cohorts (P < 0.05).
In the 2Wk-High cohort, GALC enzyme activity was signifi-
cantly increased in comparison with the IS-only–treated cohort 
in all CNS (frontal cortex, P = 0.02; cerebellar white matter, P = 
0.02; thoracic spinal cord, P = 0.04; lumbar spinal cord, P = 0.02) 
and PNS (sciatic nerve, P = 0.02) tissues analyzed except the inter-
nal capsule and cervical spinal cord (P > 0.05) (Figure 8B). Most 
notably, GALC enzyme activity was 4-fold higher than normal in 
the cerebellum, the area closest to the injection site, and 1.5-fold 
higher than normal in the sciatic nerve (Figure 8B). This corrobo-
rates our findings of GALC enzyme expression by IHC and immu-
nofluorescence (Figures 5 and 7). In the 2Wk-Low cohort at end-
point, GALC was not significantly increased in comparison with 
the IS-only cohort in any CNS or PNS tissue (P < 0.05). GALC 
levels were not significantly different from normal (P > 0.05) in 
the cerebellar white matter or sciatic nerve, suggesting an inter-
mediate level of restoration in those 2 tissues. There was no signif-
icant difference between the 2Wk-High and 2Wk-Low cohorts in 
somatic tissues (P > 0.05) (Figure 8D). A single intrathecal injec-
tion of high-dose, but not low-dose, AAV9-cGALC was able to sig-
nificantly increase GALC enzyme activity and reduce psychosine 
concentration in CNS, PNS, and somatic tissues.
To evaluate AAV9 biodistribution after intracisternal deliv-
ery, we quantified vector genome (vg) copies per diploid genome 
in untreated, 2Wk-High, and 2Wk-Low GLD dogs. In alignment 
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been shown to elicit an immune reaction even in newborn twitch-
er mice (19). In contrast, GLD in the dog results from a missense 
mutation (c.473A>C; p.158Y>S) (10) with low levels of GALC 
enzyme detectable in the CNS, PNS, and somatic tissues (ref. 17 
and Figure 7). In addition to this immunological advantage, GLD 
dogs received high-dose immunosuppression before gene transfer 
and maintenance immunosuppression for 4 months, preventing 
immune-driven decreases in transgenic protein expression. Thus, 
the canine model will likely express greater levels of both endog-
enous and transgenic GALC following AAV9-GALC therapy than 
will twitcher mice.
Importantly, presymptomatic dogs that received 2 × 1013 vg 
exhibited incomplete disease correction and the emergence of 
clinical signs not typically seen in untreated GLD dogs, which 
reach humane endpoint (pelvic limb paralysis) at a significantly 
younger age (12). The delayed progression of motor deficits seen 
in these dogs correlates with normalization of cerebellar white 
matter signal intensity and cerebellar area on MRI. While cere-
bellar disease was ameliorated, pathological signs emerging in 
2Wk-Low–treated dogs included behavioral abnormalities and 
visual deficits. Blindness is likely central in origin as no retinal 
abnormalities were observed and demyelination and perivascular 
cuffing were observed in the occipital lobes. Fascinatingly, these 
clinical findings are similar to those in late-infantile-onset and 
juvenile-onset patients, who all fall below the 5th percentile in 
cognitive development by 40 months of age, with vision deterio-
ration observed in the majority (3). These data suggest that treat-
ment with an inadequate dose of AAV9-cGALC provides insuffi-
cient GALC enzyme resulting in an attenuated form of the disease 
with substantial impairments.
Additionally, the canine model of GLD allowed for comparison 
of pre- and postsymptomatic gene delivery. Our studies found that 
postsymptomatic therapy was less effective than presymptomatic 
therapy at the respective doses evaluated. Remarkably, however, 
dogs treated with 1 × 1014 vg postsymptomatically showed slow-
ing of clinical disease progression, significantly prolonged surviv-
al, and reduced CSF protein levels. This outcome stands in stark 
contrast to HSCT, which is only effective presymptomatically (6). 
We speculate that postsymptomatically treated dogs did not fare 
as well as those treated presymptomatically because of reduced 
vg dose relative to their larger brain and body size at the time of 
treatment. Two-week-old normal dogs from this specific breeding 
line have an average brain weight of 26.06 ± 2.23 g (n = 10), while 
analogous 6-week-old dogs have an average brain weight of 52.91 
± 5.56 g (n = 10). Based on this, the dogs in the 2Wk-High cohort 
received an estimated 3.84 × 1012 vg/g of brain weight while dogs 
in the 6Wk-High cohort received an estimated 1.89 × 1012 vg/g of 
brain weight, essentially reducing the normalized dose by half. 
Notably, the single remaining dog in the 6Wk-High cohort, cur-
rently 97.1 weeks of age, was the smallest dog within that cohort 
at the time of treatment, effectively giving the dog a larger dose 
per gram of body weight and brain weight. While systemic deliv-
ery of AAV is conventionally normalized to body weight, our data 
suggest that intrathecal delivery of AAV would also benefit from 
normalization to body weight, estimated brain weight, or CSF vol-
ume. As such, we predict that normalization of dosing is likely to 
further improve prognosis for dogs treated postsymptomatically.
giant axonal neuropathy (NCT02362438). Because of its ability to 
cross the blood-brain barrier, AAV9 can be delivered intravenous-
ly to treat the CNS. However, intrathecal administration has many 
advantages, including higher transduction efficiency of the CNS 
(20); sustained expression with the absence of toxicity (21) seen 
with systemic delivery (22); evasion of anti-AAV neutralizing anti-
bodies (23), which have been shown to be detrimental to systemic 
delivery (24); and requirement of substantially less vector prod-
uct, increasing the feasibility of translation to human patients. 
Intrathecal AAV9-mediated gene therapy for Krabbe disease was 
first evaluated in the twitcher mouse (25, 26). When postnatal day 
10–11 twitcher mice received a single lumbar intrathecal injection 
at a dose of 2 × 1011 vg, survival was modestly extended by about 
10.5 days. This treatment improved the pathology and reduced 
psychosine levels but did not restore them to baseline levels (15). 
Notably, at postnatal day 10–11, twitcher mice are postsymptom-
atic, with reduced body weight and disease pathology present. 
Presymptomatic intrathecal injections were not performed, pre-
sumably because of the small size of the newborn mouse and the 
compressed timeline of disease progression.
In the GLD dog, we evaluated the efficacy of intrathecal 
administration of AAV9-cGALC in both presymptomatic and 
symptomatic dogs. Vector was administered at the cisterna mag-
na, since we and others have shown that intracisternal AAV9 
administration is safe in cats, dogs, and nonhuman primates and 
results in up to 100-fold more efficient gene transfer to the brain 
than does administration via lumbar puncture (27) or intravenous-
ly (20). Intracisternal AAV9 is currently being administered to 
patients with mucopolysaccharidosis I (NCT02362438) and GM1 
gangliosidosis (NCT04273269) in clinical trials, making this a 
clinically relevant route of administration. Herein we have estab-
lished that presymptomatic administration of high-dose (1 × 1014 
vg) AAV9-cGALC into the CSF of GLD dogs ameliorates disease 
beyond 2.5 years of age, with all dogs in the 2Wk-High cohort cur-
rently alive and neurologically normal between 92 and 136 weeks 
of age (117.2 ± 18.0, n = 6), more than 7 times longer than untreated 
GLD dogs. These dogs continue to be monitored by neurological 
examination, MRI, nerve conduction velocity testing, and brain-
stem auditory evoked response. Serum and CSF samples are rou-
tinely collected for additional long-term analyses.
The results in the dog far exceed expectations based on the 
findings in the twitcher mouse. The intrathecal dose of 2 × 1011 vg 
in the twitcher mouse is roughly equivalent to the low dose admin-
istered to GLD dogs if scaled by brain weight or CSF volume. 
Indeed, we saw a clear dose response to AAV9-cGALC in the GLD 
dogs. Reduction of the dose to 2 × 1013 vg resulted in doubling of 
lifespan in the GLD dog (untreated GLD dogs, 15.7 ± 4.8 weeks of 
age [ref. 12]; 2Wk-Low, 30.43 ± 2.65 weeks of age). Postsymptom-
atic administration of 2 × 1013 vg to dogs (6Wk-Low), the experi-
mental protocol most similar to the twitcher mice, did not signifi-
cantly increase survival time in comparison with untreated GLD 
dogs. Additionally, the twitcher mouse results from a nonsense 
mutation (c.339G>A) and makes no functional GALC protein (26). 
Twitcher mice dosed intrathecally with AAV9-mGALC did not 
receive immunosuppression (15) and thus may have developed an 
immune response that diminished transgenic protein expression. 
In fact, CNS-directed AAV-mediated gene therapy has previously 
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limb paralysis in the IS-only cohort had the highest psychosine lev-
els in the sciatic nerve (Dog 1, Supplemental Table 1). Similarly, in 
the 2Wk-Low cohort, the single dog that reached humane endpoint 
solely due to pelvic limb paralysis and not combinatorial factors of 
blindness and behavior concerns had the highest psychosine con-
centration in the sciatic nerve (Dog 16, Supplemental Table 1). It 
is hypothesized that assessment of psychosine concentrations fol-
lowing biopsy of peripheral nerves in patients may yield important 
information regarding clinical outcome.
Psychosine concentrations were highest in all cohorts in the 
internal capsule. The internal capsule was the single nervous sys-
tem tissue in which presymptomatic high-dose AAV did not nor-
malize psychosine and GALC and did not achieve a significant 
increase in vg copies. It is probable that psychosine had already 
accumulated to irreversible levels by the time of treatment at 2 
weeks of age or, alternatively, cell death and globoid cell forma-
tion in this area did not allow for sufficient transduction of thera-
peutic GALC. Ongoing studies using MALDI mass spectrometry 
will help elucidate the temporospatial accumulation of psychosine 
in canine GLD. It has recently been shown in the twitcher mouse 
that inhibitory effects of psychosine are visible as early as embry-
onic day 12 (33). Taken together, these findings reiterate the 
importance of early intervention.
Biochemical findings were corroborated by MRI and histolo-
gy. In the 2Wk-High cohort, T2-weighted hyperintensity was most 
apparent on MRI at the centrum semiovale, a region for pathology 
initiation in Krabbe disease (34, 35). Notably, the lesion was stable 
from 16 to 52 weeks, suggesting that pathology was likely present 
at the time of treatment and did not progress thereafter. Histology 
confirmed this to be a region of demyelination, necrosis, and glo-
boid cell accumulation.
Histological evaluation of GALC by IHC revealed that in 
untreated and IS-only GLD dogs GALC was detectable in globoid 
cells densely accumulated in the white matter. The same distribu-
tion was seen in the 2Wk-Low cohort, but in greater intensity like-
ly due to the prolonged age. The 2Wk-High cohort demonstrated 
cortical neurons and Purkinje cells strongly expressing GALC to 
a greater degree than normal age-matched controls, suggesting 
either the transduction of these cells or the accumulation of GALC 
due to mannose-6-phosphate receptor–mediated endocytosis. 
Quantification of IHC-positive GALC cells was not informative 
or reliable. The ability of the enzyme to actively cleave a substrate 
as measured by enzyme assay is more revealing as to the effect of 
AAV-delivered GALC.
Despite being delivered into the CSF, AAV vector copies were 
detectable in all somatic tissues analyzed. Intrathecally delivered 
AAV vectors are redistributed from the subarachnoid space to 
systemic circulation likely via the arachnoid villi (20). However, 
recent identification of the glymphatic, or glia-associated lym-
phatic, system has provided more insight into additional mech-
anisms that may control AAV clearance. Dysregulation of mem-
brane channels in aged and diseased mouse brains correlated 
with significantly increased retention of AAV vectors in the brain 
and reduced systemic leakage (36). This has yet to be investigated 
in Krabbe disease.
Although effective therapies for CNS disease are being 
developed, the current inability to treat peripheral neuropathies 
Krabbe disease in patients results from more than 200 patho-
genic variants. In patients of northern European decent, a 30-kb 
deletion and 2 missense mutations, c.1586C>T; p.T529M and 
c.1700A>C; p.Y567S, are expected to account for 50% to 60% of 
pathogenic alleles in the infantile onset (28, 29). While the natu-
rally occurring canine model has genetic limitations, the missense 
mutation may be representative of a large population of Krabbe 
disease patients and how they would respond to gene therapy. 
Since we were able to establish a robust, clinically relevant bio-
marker in the canine model, this could potentially be useful to 
normalize therapeutic responses among different mutations. 
In Krabbe disease patients, psychosine is a diagnostic marker of 
phenotype severity and treatment effect (30, 31). Similarly, we 
have shown that CSF psychosine increased early and steadily in 
untreated GLD and strongly correlated with disease progression 
(16). In the 2Wk-Low cohort, detection of psychosine in the CSF 
was delayed until 12 weeks of age. In the 2Wk-High cohort, CSF 
psychosine remained undetectable up to 24 weeks, and from 24 to 
52 weeks psychosine was detected in the CSF of only 1 dog, which 
currently remains asymptomatic. If psychosine is indeed a robust 
biomarker of therapeutic outcome, we predict that this one dog 
will eventually fare less well than other dogs in the cohort.
CSF protein concentration has recently been shown to predict 
age of disease onset and survival in a study of 248 Krabbe disease 
patients (4). Comparably, we show that CSF protein increases ear-
ly and steadily, with levels rising above normal in untreated GLD 
dogs by 8 weeks of age. Notably, CSF protein concentration in the 
2Wk-High cohort remains within normal levels beyond 52 weeks 
of age, consistent with their increased longevity and reduced 
pathology. In contrast, the 2Wk-Low and 6Wk-High cohorts 
reached above normal CSF protein levels, and the 6Wk-Low 
cohort emulated untreated GLD dogs with an early, rapid increase 
in CSF protein. The single 2Wk-High cohort dog with elevated 
psychosine also has the highest CSF protein, 21 mg/dL at 1 year of 
age, although still within normal limits.
Postmortem evaluation of the 2Wk-High cohort at 16 weeks 
of age demonstrated global transduction of the CNS with a signifi-
cant increase in GALC enzyme activity and significant reduction in 
psychosine concentration in the most rostral brain region sampled, 
the frontal cortex. GALC enzyme activity levels approximately 4 
times normal were seen in the cerebellar white matter, the tissue 
sampled closest to the injection site. Interestingly, psychosine con-
centration was below normal levels in this brain region. Despite 
attainment of supraphysiological levels of a normally low-express-
ing enzyme, no evidence of toxicity was noted in any dog, and no 
lesions were noted on MRI or on histological evaluation near the 
injection site. MRI lesions have previously been demonstrated in 
nonhuman primates, in which toxicity due to overexpression of a 
different secreted hydrolytic lysosomal enzyme occurred (32).
Variability in tissue psychosine concentrations and GALC activ-
ity was minimal within the 2Wk-High cohort, all sacrificed at 16 
weeks of age, signifying reproducibility of this treatment approach. 
In contrast, variability was seen within the IS-only and 2Wk-Low 
cohorts, which were followed until humane endpoint. We recently 
reported that CSF psychosine concentrations vary and closely cor-
relate with disease progression in GLD dogs (16), and this is likely 
true for tissues. Interestingly, the youngest dog to develop pelvic 
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treats CNS disease, intracisternal administration of AAV-GALC 
improved both CNS and PNS myelination. These results reiterate 
findings from other AAV9 clinical trials that high-dose and early 
intervention are necessary for AAV9 to provide the greatest bene-
fit. In light of safety data of intrathecal delivery of AAV9 emerging 
from clinical trials for other diseases, we believe that this positive 
finding in a large-animal model of Krabbe disease warrants timely 
translation to the clinic.
Methods
Animals, immunosuppression, and AAV vector injections. Dogs were 
raised in the National Referral Center for Animal Models of Human 
Genetic Disease of the University of Pennsylvania School of Veterinary 
Medicine (NIH P40-OD-010939). GLD in dogs is due to a missense 
mutation in the GALC gene, c.473A>C; p.158Y>S. Whole blood from 
dogs was tested for the GALC mutation as previously described (12, 17).
One hour before intracisternal injection, methylprednisolone 
was delivered intravenously at a dose of 20 mg/kg. Immediately 
before intracisternal injection, the skin was clipped and scrubbed 
with 4% chlorohexidine followed by 70% isopropyl alcohol, and 
approximately 0.5 mL of CSF was collected from the cerebellomed-
ullary cistern. Then 1.0 mL of AAV9-cGALC was delivered as a bolus 
over less than 1 minute. Dogs received oral prednisone at a dose of 
0.5 mg/kg daily for 4 months followed by a 2-week taper. GLD dogs 
were euthanized using an overdose of intravenous barbiturate at a 
predetermined or standard humane endpoint. After sacrifice, ani-
mals were perfused through the left ventricle with 0.9% cold saline 
and tissues collected.
Vector production. AAV9-cGALC vector was produced with sin-
gle-stranded AAV genome comprising an AAV2 inverted terminal 
repeat (ITR), the CAGGS version of the CBA promoter (1.6 kb total 
CMV enhancer, chicken β-actin promoter, and partial 5′-untranslated 
region), codon-optimized canine GALC DNA coding sequence (2055 
bp), SV-40 polyadenylation signal (143 bp), and an AAV2 ITR. AAV 
vectors were produced at the University of North Carolina Vector Core 
as previously described (45). Purified AAV was dialyzed in PBS sup-
plemented with 5% d-sorbitol and an additional 212 mM NaCl (350 
mM NaCl total). Vector was titered by quantitative PCR (46), and con-
firmed by PAGE and silver stain.
Nerve conduction velocity, brainstem auditory evoked response, and 
MRI. Dogs were anesthetized with propofol, endotracheally intu-
bated, and maintained on isoflurane anesthesia. Nerve conduction 
velocity was tested using an electrodiagnostics machine (Nicolet 
Viking Quest). Brainstem auditory evoked response data were record-
ed using a Nicolet Viking Quest machine (Nicolet Biomedical). Imag-
ing was performed on anesthetized dogs on a 1.5-tesla MRI scanner 
(Signa, GE Corp.). Nerve conduction velocity testing, brainstem audi-
tory evoked response recording, and MRI were performed as previ-
ously described (12, 13, 17).
Histology. Perfused brains were fixed in 4% paraformaldehyde 
and paraffin-embedded. Myelin staining and periodic acid–Schiff 
staining were performed as previously described (12, 17). For immu-
nofluorescence, deparaffinized and rehydrated slides were heated to 
a boil followed by a 30-minute incubation in antigen retrieval solution 
(HK086, Biogenex). Primary rabbit polyclonal anti-GALC (AB137750, 
Abcam; 1:200) and rat monoclonal anti–myelin basic protein (NB600-
717, Novus Biologics; 1:500) antibodies were diluted in antibody dilu-
continues to impact the prognosis for patients with many lyso-
somal storage diseases. While cognitive function is improved 
in infants with Krabbe disease who receive HSCT, motor defi-
cits and peripheral nerve dysfunction often persist (6, 37, 38). 
Here, in the canine GLD model, early delivery of high-dose, but 
not low-dose, AAV9-cGALC resulted in a significant increase in 
GALC enzyme activity and significant reduction of psychosine 
to below normal levels in the sciatic nerve after intracisternal 
delivery. Levels of GALC in the 2Wk-High cohort are 3.5 times 
higher in the sciatic nerve than in the liver, suggesting that the 
correction to the PNS is not due to leakage of vector or GALC 
into the periphery. The increase in sciatic nerve GALC activi-
ty could be due either to transduction of the lower motor neu-
ron or dorsal root ganglia, resulting in increased axonal GALC, 
or to transduction of Schwann cells. The delivery of lysosomal 
enzymes to Schwann cells and axons of peripheral nerves has 
been previously described in dogs with mucopolysaccharido-
sis VII that received canine GUSB via intracisternally delivered 
AAV (39) and likely results from AAV passage down the nerves 
through endoneurial fluid (40–42) or axonal transport (43, 44). 
Importantly, in this study, nerve conduction velocity testing and 
PNS ultrastructure analysis show improved PNS myelination in 
treated dogs and corroborate the biochemical findings. Together, 
these findings provide what is to our knowledge the first demon-
stration of clinical, biochemical, and histological correction of 
PNS abnormalities in a large-animal model following intracister-
nal delivery of AAV9. This finding holds implications for treat-
ment of other peripheral nerve disorders using this safe, effec-
tive, and proven route of administration.
We previously evaluated combination intravenous and 
intracerebroventricular administration of AAVrh10 in canine 
GLD (17). The studies cannot be directly compared because of 
different AAV serotypes, routes of administration, doses, and 
immunosuppression protocols. Nonetheless, intracisternal 
AAV9 evaluated herein resulted in what we believe to be the 
first extension of lifespan beyond 1 year of age in the GLD dog 
and more global correction of nervous system disease. Addi-
tionally, intracisternal delivery allowed for earlier intervention 
and required significantly less vector, permitting higher dosing 
and a more robust study design. Intracisternal AAV9 has shown 
unprecedented results in this large-animal model and is the most 
translatable approach evaluated to date. Long-term evaluation of 
the immune response to AAV9-cGALC, and its relation to circu-
lating GALC enzyme activity, is ongoing and will be reported at 
the 2-year time point. Additionally, assessment of lumbar intra-
thecal delivery of AAV9-cGALC is under way and will help guide 
translation to the clinic.
Conclusions. In this robust study of 26 GLD dogs, we demon-
strated that intracisternal delivery of 1 × 1014 vg AAV9-GALC into 
presymptomatic GLD dogs ameliorated neurological signs of dis-
ease beyond 2.5 years of age. Reducing the dose 5-fold resulted 
in significant extension of lifespan; however, an attenuated form 
of Krabbe disease developed, including behavioral abnormalities 
and blindness. Administration of 1 × 1014 vg at a symptomatic age, 
when HSCT no longer has clinical benefit, significantly extend-
ed lifespan and delayed disease progression, with 1 dog still alive 
beyond 1.5 years of age. Finally, in contrast to HSCT, which only 
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Vector quantification. Vector biodistribution was done by quan-
titative PCR. Tissue DNA was purified and quantified as previ-
ously described (24) except that a QIACube HT system was used 
for genomic DNA purification. Quantification was directed to the 
codon-optimized canine GALC transgene, using primers that would 
not recognize the endogenous GALC gene. The primer sequences 
were as follows: cGALC-F-5′-GGCGTCCATGCTGCTTGATAG-3′; 
cGALC-R-5′-ACATCGCTGTTCAGGGTGGAG-3′; cSDHA-F-5′-GC-
GTTCCACTTGTCCCTGTA-3′; cSDHA-R-5-TCATCACTTCCCAA-
CCTGGC-3′. Data are reported as the number of double-stranded 
GALC molecules per 2 double-stranded copies of the canine SDHA 
locus (the number of vector DNA copies per diploid canine genome).
Statistics. Data were evaluated for normal distribution by the skew-
ness and kurtosis tests for normality, and the nonparametric Kruskal- 
Wallis test was used for the initial comparison of each variable between 
the different treatment groups. The Mann-Whitney test was performed 
for follow-up pairwise comparisons if the P value of the Kruskal-Wallis 
test was less than 0.05. A P value of less than 0.05 on the Mann-Whitney 
test, which does not assume that the variable is normally distributed, was 
considered significant. All statistical evaluations were performed using a 
statistical software package (Stata 14.0 for Macintosh, Stata Corp.).
Study approval. Dogs were raised in the National Referral Center for 
Animal Models of Human Genetic Disease of the University of Penn-
sylvania School of Veterinary Medicine (NIH P40-OD-010939) under 
NIH and US Department of Agriculture guidelines for the care and use 
of animals in research. The experimental protocol was approved by the 
University’s Institutional Animal Care and Use Committee.
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ent solution (003118, Life Technologies) and incubated at 37°C for 1 
hour. Following three 5-minute washes with PBS, donkey anti–rabbit 
IgG conjugated to Alexa Fluor 568 (A10042, Thermo Fisher Scientif-
ic) and donkey anti–rat IgG conjugated to Alexa Fluor 488 (A21208, 
Thermo Fisher Scientific) secondary antibodies were diluted 1:500 in 
antibody diluent solution and incubated at 37°C for 30 minutes. Fol-
lowing three 5-minute washes with PBS, slides were stained with DAPI 
for 1 minute and mounted. For IHC, following rehydration and anti-
gen retrieval, slides were incubated in 3% hydrogen peroxide for 15 
minutes to quench endogenous peroxidases and then rinsed. Sections 
were blocked for endogenous biotin with an avidin/biotin blocking 
kit (SP-2001, Vector Laboratories). GALC antibody was diluted and 
incubated as described for immunofluorescence, washed 3 times for 
5 minutes in PBS, and incubated with a 1:500 dilution of biotinylated 
goat anti–rabbit IgG secondary antibody (BA-1000, Vector Laborato-
ries) at 37°C for 30 minutes. Following three 5-minute PBS washes, 
sections were incubated with avidin–biotin–horseradish peroxidase 
complex (PK-6100, Vector Laboratories) at 37°C for 30 minutes. Fol-
lowing three 5-minute PBS washes, colorimetric signal was developed 
using a DAB kit (SK-4100, Vector Laboratories). Sections were dehy-
drated through ethanols, cleared in xylene, and mounted with Cyto-
seal XYL (8312-4, Thermo Fisher Scientific).
Detailed histological evaluation was performed in a blind fashion 
without knowledge of the experimental groups by a board-certified 
pathologist. Semiquantitative analysis of globoid cell accumulation, 
gliosis, and inflammation was performed on H&E sections, while 
the evaluation of demyelination was performed on adjacent sections 
stained with iron eriochrome stain.
Peripheral nerve analysis: light microscopy and morphometry. 
Peripheral nerve specimens were collected from the tibial nerves and 
prepared as previously described (12, 17). Qualitative morphometry 
was performed on nerve fibers adequately fixed and free of artifacts. 
Determinations included myelinated fiber density, split myelinated 
fiber density, thin myelinated fiber density, and cluster density.
Quantification of tissue GALC enzyme activity. Tissue homogenates 
(20 μg) in pure H2O were incubated with fluorescent GALC substrate 
(6HMU-β-d-galactoside, Moscerdam Substrates) for 17 hours at 37°C. 
Enzymatic activity was assessed via fluorescence measured with a 
Beckmann Coulter DTX 880 multimode detector using excitation/
emission wavelengths of 385 nm/450 nm.
Quantification of tissue psychosine. Psychosine from tissue homog-
enates (200 μg) was extracted via a methanol–acetic acid solution and 
analyzed as previously described (47). Analysis was then performed 
on a Shimadzu Nexera ultra-high-performance liquid chromatography 
system equipped with a Waters Acquity UPLC BEH amide column and 
coupled to a Shimadzu LCMS-8050 triple quadrupole mass spectrome-
ter equipped with positive ion electrospray. d-Lactosyl-β1-1′-d-erythro- 
sphingosine (Avanti Polar Lipids) was used as an internal standard.
Quantification of CSF psychosine. CSF psychosine was determined 
as previously described (48). Protein precipitation was performed to 
extract psychosine from 50 μL of dog CSF. Deuterated galactosyl-
sphingosine (psychosine-d5; 1 ng/mL) was used as an internal stan-
dard. Sample analysis was performed with a Shimadzu 20AD HPLC 
system, coupled to a triple quadrupole mass spectrometer (API 4000 
QTrap) operated in MRM mode. The positive ion ESI mode was used 
for detection of psychosine and psychosine-d5. Data processing was 
conducted with Analyst 1.5.1 (Applied Biosystems).
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